BioSpace News Archive

A phlebotomist is responsible for completing several types of bloodwork activities, including the drawing of patient blood to conduct tests and to store blood donations.

The area of immunotherapy and immuno-oncology has exploded in the last few years, but researchers are focused on improving the techniques.

Partnership in iABC project will accelerate Alaxia’s development of promising antimicrobial therapy for cystic fibrosis

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, is providing an update outlining the Company’s US regulatory strategy following its pre-submission meeting with the U.S. Food and Drug Administration.

Proteostasis Therapeutics, Inc. announced that the Company’s cystic fibrosis transmembrane conductance regulator modulators will be highlighted in five presentations at the North American Cystic Fibrosis Conference from October 31 – November 2, 2019 at the Nashville Music City Center in Nashville, Tennessee.

CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential

Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo flat dosing schedule of 240 mg infused over 30 minutes every two weeks or 480 mg infused over 60 minutes every four weeks for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

TG Therapeutics, Inc. announced that final long-term results from the Phase 3 GENUINE study demonstrated that ublituximab in combination with ibrutinib improved progression-free survival (PFS), as determined by Independent Review Committee.

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), announced that the Company believes it remains on target to report top-line data from the global Phase 3 INSPIRE Trial with intravenous (IV) rigosertib in second-line, higher-risk MDS patients in the first half of 2020 following full enrollment and 288 death events.

Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP)